Videos

Although pharmaceutical companies have already begun developing COVID-19 vaccine boosters, Michael Haydock of Informa Pharma Intelligence said boosters may not be necessary in the fall of 2021.

In an interview with Pharmacy Times® and Directions in Oncology Pharmacy®, Abizer Gaslightwala, vice president and head of the U.S. Hematology and Oncology division at Jazz Pharmaceuticals discusses the company’s new digital resource, Nothing Small About It.

Mary Reed, DrPH, research scientist at Kaiser Permanente, discussed how COVID-19 forced health systems to shift primarily to telehealth, and the impact this had on patients with diabetes.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed what some of the adverse events experienced by patients were, and how patients were able to handle them.

Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discussed the importance of the FDA’s expedited approval process for infigratinib in the treatment of previously treated locally advanced or metastatic cholangiocarcinoma.

The keys to this recovery will be innovation and collaboration, according to Craig Dolan, PharmD, MBA, of McKesson RxO.

Preventive therapies available for patients who require migraine prophylaxis and factors that impact treatment selection.

Jennifer L. Mazan, PharmD, describes the role of CGRP antagonists as acute migraine treatment and shares considerations for selecting and using these therapies.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed why the research assessing dapagliflozin advanced from cardiorenal effects to prevention and organ protection.

Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discussed how the US FDA evaluated the application for infigratinib to expedite the approval process for treatment of previously treated locally advanced or metastatic cholangiocarcinoma.

The drug is approved for patients after 4 or more failed lines of therapy, although many patients in clinical trials had received 7 or more prior lines of therapy.

Anastasia Abramson, PharmD, MBA, reviews the dispensing process for factor VIII and emicizumab, also emphasizing the importance of patient education.

A panel of experts discuss the role of specialty pharmacies in managing hemophilia A as well as transitioning patients from the inpatient to outpatient care setting.

Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses how the results from the phase 3 trial evaluating an investigational 2 mg dose of semaglutide could change treatment options for patients with type 2 diabetes.

Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discussed the dosing and treatment cycle during the trial assessing infigratinib for the treatment of previously treated locally advanced or metastatic cholangiocarcinoma.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed why the results of the DARE-19 trial are important to the field, especially during the COVID-19 pandemic.

As the first point of contact at many pharmacies, technicians can often see whether a patient has been prescribed an opioid or other monitored substances.

A panel of experts builds a discussion on the role of angiotensin receptor-neprilysin inhibitors for the management of heart failure and highlights the importance of considering patient adherence and cost burden.

Key opinion leader in pharmacy, Randy McDonough, PharmD, MS, BCGP, BCPS, FAPhA, provides insight into the history of conventional treatment approaches in heart failure.

Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the benefit of the investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed how the phase 3 DARE-19 trial was conducted to assess dapagliflozin in patients with type 2 diabetes hospitalized with COVID-19.

Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discussed the safety profile of infigratinib for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma.

Panzyga is indicated for the treatment of primary humoral immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and chronic immune thrombocytopenia.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the safety profile of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19 during the DARE-19 trial.

Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discusses the eligibility requirements for patients included in the phase 2 trial results that led to the FDA approval of infigratinib.

Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the adverse events experienced by patients during the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes.

Sacituzumab govitecan is approved for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received 2 more prior systemic therapies.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the efficacy of dapagliflozin in the DARE-19 trial assessing its efficacy and safety in patients with type 2 diabetes hospitalized with COVID-19.

Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses how the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes was conducted.

Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discussed the findings of the phase 2 trial assessing infigratinib for treatment of previously treated locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.